Cargando…

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Bashiri, Hamed, Khalilnezhad, Ahad, Totani, Haruhito, Tae-Hoon, Chung, Joo Chng, Wee, Yeong, Joe, Suda, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431032/ http://dx.doi.org/10.1097/01.HS9.0000970236.23384.06

Ejemplares similares

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

CCM 83.3
Publicado: (1983)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

833. Characteristics and Utilization Patterns of Colistin Compared with Newer Agents in Gram-Negative Infections
por: Marcella, Stephen, et al.
Publicado: (2020)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
por: Bashiri, Hamed, et al.
Publicado: (2023)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
por: Risitano, A., et al.
Publicado: (2022)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
por: Reghunathan, Renji, et al.
Publicado: (2013)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
por: Bi, Chonglei, et al.
Publicado: (2015)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
por: D’Amico, Ronald, et al.
Publicado: (2021)

833. Interaction between Aspergillus fumigatus and non-tuberculous mycobacteria
por: Namie, Hotaka, et al.
Publicado: (2023)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim
por: Mustafa, Nurulhuda, et al.
Publicado: (2017)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
por: Jia, Yunlu, et al.
Publicado: (2021)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Emergence of OXA-833 in Proteus Species at a Tertiary Care Hospital in Dhaka, Bangladesh
por: Jannat, Hasnatul, et al.
Publicado: (2021)

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
por: Li, Boheng, et al.
Publicado: (2019)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

P912: COVID19 SEVERITY AND THERAPEUTIC OPTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Karimova, E., et al.
Publicado: (2022)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

Plasma Cell Neoplasms: Genetics, Pathobiology, and New Therapeutic Strategies
por: Lee, Dong Soon, et al.
Publicado: (2014)

Results of the Consensus Finding Study Group on Autoantibodies (March 2003–March 2004)
por: Hamann, D, et al.
Publicado: (2005)

Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
por: Lehne, G., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_dacmbp0h5j3dcjoturcddaqjgi